Early clearance for R-B, Adams
This article was originally published in The Tan Sheet
Executive Summary
Slough, U.K.-based Reckitt Benckiser on Jan. 8 announced the receipt of an early termination of the waiting period under the Hart-Scott-Rodino Act regarding its offer to purchase all outstanding shares of Adams Respiratory Therapeutics' stock. Through its wholly owned subsidiary Twickenham, Reckitt, a household cleaning, health and personal care product firm, made an offer in December to purchase all Chester, N.J.-based Adams' outstanding stock for $60 per share (1"The Tan Sheet" Dec. 17, 2007, p. 5)...
You may also be interested in...
Reckitt Benckiser Looks Overseas To Double Adams’ Revenue
Reckitt Benckiser should meet its goal of doubling Adams Respiratory Therapeutics' revenues by launching the firms' OTC cough and congestion products overseas and introducing new products being developed by Adams in the United States, analysts and Reckitt executives say
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.